Adipocyte and lipid metabolism in cancer drug resistance

Development of novel and effective therapeutics for treating various cancers is probably the most congested and challenging enterprise of pharmaceutical companies. Diverse drugs targeting malignant and nonmalignant cells receive clinical approval each year from the FDA. Targeting cancer cells and nonmalignant cells unavoidably changes the tumor microenvironment, and cellular and molecular components relentlessly alter in response to drugs. Cancer cells often reprogram their metabolic pathways to adapt to environmental challenges and facilitate survival, proliferation, and metastasis. While cancer cells' dependence on glycolysis for energy production is well studied, the roles of adipocytes and lipid metabolic…

• SC
  Swedish Cancer Foundation
• KI
  Karolinska Institutet
• KO
  Knut och Alice Wallenbergs Stiftelse
• NN
  Novo Nordisk
• V
  Vetenskapsrådet
• NN
  Novo Nordisk Fonden